Stoke Therapeutics names Solid Biosciences CEO Bo Cumbo to board
Bitget2026/09/23 20:01- Stoke Therapeutics appointed Bo Cumbo to its board.
- Edward Kaye retired as a director; he served on the board since 2017 and was CEO from 2017 to March 2025.
- Cumbo has led rare-disease commercial launches; he is CEO and a director at Solid Biosciences.
- He previously held senior commercial roles at Sarepta Therapeutics, including chief commercial officer, with earlier roles at Vertex and Gilead.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
